Home › Funds › Portolan Capital Management, LLC › HALO
Portolan Capital Management, LLC position in HALO
HALOZYME THERAPEUTICS INC · Health Care
Portolan Capital Management, LLC reported holding 246,613 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$27.2M, representing 1.13% of its reported portfolio and ranking #27 among its reported holdings. Portolan Capital Management, LLC has disclosed HALO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Portolan Capital Management, LLC's HALO position evolved
Portolan Capital Management, LLC first disclosed a stake in HALO in Q2 2026 at 127,498 shares (US$10.0M). The position peaked in Q3 2026 at 246,613 shares, worth US$27.2M. Across 2 filings, Portolan Capital Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 246,613 shares valued at US$27.2M — an increase of 119,115 shares quarter over quarter.. Notable position changes include a 93% increase in Q3 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 127.50K | $9.98M | New |
| Q3 2026 | 246.61K | $27.23M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About HALO and 13F data
HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$244.3M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding HALO
- CONGRESS ASSET MANAGEMENT CO 2.28M sh · $251.89M · Q3 2026
- SNYDER CAPITAL MANAGEMENT L P 2.21M sh · $244.28M · Q3 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.62M sh · $178.46M · Q3 2026
- FULLER & THALER ASSET MANAGEMENT, INC. 1.60M sh · $176.98M · Q3 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 1.58M sh · $174.27M · Q3 2026
- Stephens Investment Management Group LLC 1.41M sh · $156.00M · Q3 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.19M sh · $131.90M · Q3 2026
- GW&K Investment Management, LLC 1.14M sh · $125.86M · Q3 2026
- WASATCH ADVISORS LP 1.05M sh · $115.88M · Q3 2026
- Boston Trust Walden Corp 1.04M sh · $114.35M · Q3 2026
More on Portolan Capital Management, LLC
FAQ
How long has Portolan Capital Management, LLC held HALO?
Portolan Capital Management, LLC has disclosed HALO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Portolan Capital Management, LLC's current position in HALO?
As of Q3 2026, Portolan Capital Management, LLC holds 246.61K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $27.23M, representing 1.13% of its reported portfolio and ranking #27.
Has Portolan Capital Management, LLC been buying or selling HALO?
In the latest 13F filing (Q3 2026), Portolan Capital Management, LLC increased its position in HALO. The position peaked in Q3 2026 at 246.61K shares.
Which other funds hold HALO?
Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.